View in EDS PDF Full Text

High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.

Saved in:
Bibliographic Details
Title: High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
Authors: Jansen MP; Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Erasmus Medical Center Rotterdam, Room Be401, PO Box 2040, 3000 CA Rotterdam, The Netherlands. m.p.h.m.jansen@erasmusmc.nl, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, Rodríguez-González FG, Heine AA, Martens JW, Sleijfer S, Foekens JA, Berns EM
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2012 Jun; Vol. 133 (3), pp. 937-47. Date of Electronic Publication: 2011 Nov 18.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 22094936
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jansen+MP%22">Jansen MP</searchLink>; Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Erasmus Medical Center Rotterdam, Room Be401, PO Box 2040, 3000 CA Rotterdam, The Netherlands. m.p.h.m.jansen@erasmusmc.nl<br /><searchLink fieldCode="AU" term="%22Reijm+EA%22">Reijm EA</searchLink><br /><searchLink fieldCode="AU" term="%22Sieuwerts+AM%22">Sieuwerts AM</searchLink><br /><searchLink fieldCode="AU" term="%22Ruigrok-Ritstier+K%22">Ruigrok-Ritstier K</searchLink><br /><searchLink fieldCode="AU" term="%22Look+MP%22">Look MP</searchLink><br /><searchLink fieldCode="AU" term="%22Rodríguez-González+FG%22">Rodríguez-González FG</searchLink><br /><searchLink fieldCode="AU" term="%22Heine+AA%22">Heine AA</searchLink><br /><searchLink fieldCode="AU" term="%22Martens+JW%22">Martens JW</searchLink><br /><searchLink fieldCode="AU" term="%22Sleijfer+S%22">Sleijfer S</searchLink><br /><searchLink fieldCode="AU" term="%22Foekens+JA%22">Foekens JA</searchLink><br /><searchLink fieldCode="AU" term="%22Berns+EM%22">Berns EM</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228111104%22">Breast cancer research and treatment</searchLink> [Breast Cancer Res Treat] 2012 Jun; Vol. 133 (3), pp. 937-47. <i>Date of Electronic Publication: </i>2011 Nov 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Kluwer+Academic%22">Kluwer Academic </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8111104 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-7217 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676806%22">01676806 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res Treat <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=22094936
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10549-011-1877-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 937
    Titles:
      – TitleFull: High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jansen MP
      – PersonEntity:
          Name:
            NameFull: Reijm EA
      – PersonEntity:
          Name:
            NameFull: Sieuwerts AM
      – PersonEntity:
          Name:
            NameFull: Ruigrok-Ritstier K
      – PersonEntity:
          Name:
            NameFull: Look MP
      – PersonEntity:
          Name:
            NameFull: Rodríguez-González FG
      – PersonEntity:
          Name:
            NameFull: Heine AA
      – PersonEntity:
          Name:
            NameFull: Martens JW
      – PersonEntity:
          Name:
            NameFull: Sleijfer S
      – PersonEntity:
          Name:
            NameFull: Foekens JA
      – PersonEntity:
          Name:
            NameFull: Berns EM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2012 Jun
              Type: published
              Y: 2012
          Identifiers:
            – Type: issn-electronic
              Value: 1573-7217
          Numbering:
            – Type: volume
              Value: 133
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Breast cancer research and treatment
              Type: main
ResultId 1